Acetazolamide for Treatment Resistant Schizophrenia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Acetazolamide for Treatment Resistant Schizophrenia — Stella

Home/Schizophrenia/

View on ClinicalTrials.gov

Recruiting

Back to Schizophrenia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

University of Pittsburgh, Pittsburgh, Pennsylvania

India

St John's Medical College Hospital, Bangalore

Key details

Phase

Early testing / Safety & dosing

Sponsor

Vishwajit Nimgaonkar, MD PhD

Collaborators

Stanley Medical Research Institute

Enrollment target

~60 participants

Started

February 2022

Primary completion

June 2026

Age range

18 Years – 55 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.